Focused On-demand Library for Microtubule-associated tyrosine carboxypeptidase 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q68EN5

UPID:
MACA1_HUMAN

ALTERNATIVE NAMES:
Microtubule-associated tyrosine carboxypeptidase

ALTERNATIVE UPACC:
Q68EN5; A2VCS8; Q8N3H9; Q8NAQ5; Q96IE5

BACKGROUND:
The enzyme Microtubule-associated tyrosine carboxypeptidase 1 is distinguished by its unique function of cleaving the C-terminal residues of alpha-tubulin, a process vital for microtubule stability and function. This specificity towards tubulin dimers underscores its significance in maintaining the cellular architecture and intracellular transport mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Microtubule-associated tyrosine carboxypeptidase 1 holds promise for unveiling novel therapeutic avenues. Given its integral role in microtubule dynamics, targeting this protein could lead to innovative treatments for diseases where microtubule function is compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7394 of 8789